Detailed Information on Publication Record
2016
Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas
ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, David ŠÁLEK, Jiří JARKOVSKÝ, Jan ŠMARDA et. al.Basic information
Original name
Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas
Authors
ZLÁMALÍKOVÁ, Lenka (203 Czech Republic), Mojmír MOULIS (203 Czech Republic), David ŠÁLEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Jan ŠMARDA (203 Czech Republic, belonging to the institution) and Jana ŠMARDOVÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition
Oncology Reports, Athens, Spandidos Publications, 2016, 1021-335X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10601 Cell biology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.662
RIV identification code
RIV/00216224:14310/16:00089581
Organization unit
Faculty of Science
UT WoS
000374077700021
Keywords (in Czech)
lymfom mantlových buněk; difúzní lymfom velkých B-buněk; cykliny D; qRT-PCR; immunoblotting
Keywords in English
mantle cell lymphoma; diffuse large B- cell lymphoma; D-type cyclins; qRT-PCR; immunoblotting
Tags
International impact, Reviewed
Změněno: 19/2/2018 11:36, prof. RNDr. Jan Šmarda, CSc.
Abstract
V originále
D-type cyclins are involved in cell cycle regulation and play an important role in the pathogenesis of lymphomas. Aberrant expression of cyclin D1 is associated with mantle cell lymphoma (MCL) and serves as a diagnostic marker of MCL. Analysis of cyclin D expression in tumor tissues of patients with diffuse large B-cell lymphoma (DLBCL) which comprises a heterogeneous group of tumors may contribute to their stratification. We analyzed expression of cyclin D1, D2, and D3 mRNAs in 30 MCL and 104 DLBCL patients using qRT-PCR and addressed their significance for disease outcome. We confirmed a high level of cyclin D1 mRNA in 29 MCL cases (97%). One case (3%) was identified as positive for cyclin D2. Expression of cyclin D1 was limited to MCL and did not occur in DLBCL. Overexpression of cyclin D2, which is rare in MCL, occurred more frequently in DLBCL (11 cases, 10.6%). We showed that high expression of cyclin D2 in DLBCL cases de novo decreased the overall survival rate (P=0.016) and progression-free survival (P=0.009). The expression pattern of cyclin D3 was similar in both types of studied lymphomas and it did not affect the disease outcome.